累积发病率
医学
单变量分析
内科学
入射(几何)
无进展生存期
造血细胞
回顾性队列研究
造血干细胞移植
移植
外科
多元分析
化疗
造血
物理
光学
生物
遗传学
干细胞
作者
Mazyar Shadman,Kwang Woo Ahn,Manmeet Kaur,Lazaros J. Lekakis,Amer Beitinjaneh,Madiha Iqbal,Nausheen Ahmed,Brian T. Hill,Nasheed Hossain,Peter A. Riedell,Ajay K. Gopal,Natalie S. Grover,Matthew J. Frigault,Jonathan E. Brammer,Nilanjan Ghosh,Reid W. Merryman,Aleksandr Lazaryan,Ron Ram,Mark Hertzberg,Bipin N. Savani
标识
DOI:10.1038/s41408-024-01084-w
摘要
Abstract In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months for the auto-HCT and 24.7 months for the CAR-T cohort. Patients ages 18 and 75 with a diagnosis of DLBCL were included if they received auto-HCT ( n = 281) or commercial CAR-T ( n = 79) while in a CR. Patients undergoing auto-HCT with only one prior therapy line and CAR-T patients with a previous history of auto-HCT treatment were excluded. Endpoints included Progression-free survival (PFS), relapse rate, non-relapse mortality (NRM) and overall survival (OS). In univariate analysis, treatment with auto-HCT was associated with a higher rate of 2-year PFS (66.2% vs. 47.8%; p < 0.001), a lower 2-year cumulative incidence of relapse (27.8% vs. 48% ; p < 0.001), and a superior 2-year OS (78.9% vs. 65.6%; p = 0.037). In patients with early (within 12 months) treatment failure, auto-HCT was associated with a superior 2-year PFS (70.9% vs. 48.3% ; p < 0.001), lower 2-year cumulative incidence of relapse (22.8% vs. 45.9% ; p < 0.001) and trend for higher 2-year OS (82.4% vs. 66.1% ; p = 0.076). In the multivariable analysis, treatment with auto-HCT was associated with a superior PFS (hazard ratio 1.83; p = 0.0011) and lower incidence of relapse (hazard ratio 2.18; p < 0.0001) compared to CAR-T. In patients with relapsed LBCL who achieve a CR, treatment with auto-HCT is associated with improved clinical outcomes compared to CAR-T. These data support the consideration of auto-HCT in select patients with LBCL achieving a CR in the relapsed setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI